FDA Approved: ILARIS — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for ILARIS (canakinumab) submitted by Novartis Pharmaceuticals Corporation, resulting in an update/expansion of the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes
• Familial Cold Autoinflammatory Syndrome
• Muckle-wells Syndrome
• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• ILARIS (canakinumab)

Snippet

SUPPL AP for ILARIS (CANAKINUMAB)